News

MetaVia Advances Clinical Trials for Obesity Drug DA-1726

MetaVia Advances Clinical Trials for Obesity Drug DA-1726

MetaVia Advances Clinical Trials for DA-1726

MetaVia Inc. (Nasdaq: MTVA), a biotechnology company dedicated to transforming the treatment of cardiometabolic diseases, has recently achieved an important milestone in its Phase 1 clinical trial of the drug DA-1726. The company has extended the trial period from 4 weeks to 8 weeks for the 48 mg multiple ascending dose (MAD) cohort and has administered the fifth weekly dose to the first participating patient.

DA-1726 is characterized as a dual oxyntomodulin (OXM) analog that engages two critical receptors, glucagon-like peptide-1 (GLP-1) and glucagon receptors (GCGR), which are pivotal in addressing obesity. The extension of the trial is designed to provide insights into the drug's long-term safety, tolerability, and efficacy. In particular, MetaVia aims to explore the maximum tolerated dose without titration over this longer span.

Understanding the Objectives of the Extended Trial

In a statement, Hyung Heon Kim, President and CEO of MetaVia, outlined the significance of the 4-week extension, emphasizing the potential to gather more comprehensive data on DA-1726. This information could enhance its positioning against current obesity treatments and those in advanced stages of clinical trials. The company aims to fully assess DA-1726's therapeutic profile, including its impact on primary and secondary endpoints such as safety, tolerability, body weight, waist circumference, and body mass index (BMI).

Previous data from the 32 mg dose indicated promising outcomes, with participants experiencing a mean weight loss of 4.3% and some achieving up to 6.3% by Day 26. Additionally, 83% of the patients reported early satiety, and significant waist reductions were noted by Day 33. This data bolsters expectations that DA-1726 may deliver superior tolerability compared to existing GLP-1 therapies.

Trial Design and Objectives

The Phase 1 trial itself is structured as a randomized, double-blind, placebo-controlled study aimed at assessing the safety, pharmacokinetics, and pharmacodynamics of DA-1726 among obese, otherwise healthy subjects. Participants were enrolled with a BMI ranging from 30 to 45 kg/m², structured in cohorts where each subject either received the drug or a placebo across several weekly administrations.

With the extension, subjects will experience an additional four weekly doses of DA-1726, bringing the total exposure duration to 8 weeks. Primary endpoints focus on evaluating the safety and tolerability by monitoring adverse reactions, while secondary endpoints are centered around the pharmacokinetics of the drug at its highest doses.

Significance of DA-1726 in Obesity Treatment

DA-1726 is particularly notable for being an oxyntomodulin (OXM) analog that is expected to be administered once weekly via subcutaneous injection. Its dual-action mechanism promotes weight loss by suppressing appetite and enhancing energy expenditure. In preclinical studies, DA-1726 has shown superior weight loss compared to several existing treatments, demonstrating an ability to deliver positive results while encouraging healthier metabolic responses.

The Future of MetaVia's Development

Looking ahead, MetaVia continues to advance its research efforts, not just with DA-1726, but also with DA-1241, which aims to address Metabolic Dysfunction-Associated Steatohepatitis (MASH). This commitment to innovation in the field of cardiometabolic disorders places MetaVia at the forefront of biotechnology and therapeutic solutions.

With the ongoing development of DA-1726 and its potential applications, the industry watches closely for the forthcoming top-line data that is expected in the near future. The anticipation surrounding this data will be crucial for validating DA-1726's efficacy and safety, positioning it as a promising candidate in the landscape of obesity treatments.

Frequently Asked Questions

What is the aim of MetaVia's Phase 1 clinical trial for DA-1726?

The trial aims to evaluate the safety, tolerability, and efficacy of DA-1726 in obese patients over an extended period of 8 weeks.

How does DA-1726 work?

DA-1726 acts as a dual agonist of GLP-1 and glucagon receptors, leading to weight loss through reduced appetite and increased energy expenditure.

What were the significant outcomes from the previous 32 mg dose studies?

Participants experienced a mean weight loss of 4.3%, reported early satiety in 83% of cases, and noted significant waist reductions.

Why is the extension to 8 weeks significant for the clinical trial?

This additional time allows for a more robust evaluation of the drug’s therapeutic profile and its long-term safety and efficacy.

What other products is MetaVia developing besides DA-1726?

MetaVia is also working on DA-1241, aimed at treating MASH and promoting healthier metabolic responses.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 295

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 112

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 98

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Long-Term Value Growth of Digital Realty Trust

Updated Category News Views 203

Digital Realty Trust: A 20-Year Journey of Growth Digital Realty Trust (NYSE: DLR) stands as a beacon of successful investing over the past two decades, consistently yielding remarkable returns. Rolling forward from the turn of the millennium to the current day, an investment made in this data center REIT has not just maintained its value but has outperformed traditional...

Continue Reading
Robotic Innovations Drive Future of Inspection and Maintenance Market

Updated Category News Views 187

Inspection and Maintenance Robots Market Overview The Inspection and Maintenance Robots Market is set to witness significant growth as industries embrace automation for improved efficiency and safety. According to market analysts, the size was valued at USD 41.66 billion in 2023 and is expected to soar to USD 146.9 billion by 2032, translating to a compound annual growth...

Continue Reading
Exploring the Growth of the Sports Analytics Market

Updated Category News Views 266

Understanding the Sports Analytics Market The Sports Analytics Market is experiencing notable expansion, primarily fueled by the rising demand for AI-driven analytics, the need for real-time performance insights, and enhanced strategies for player and team management. Despite its growth, challenges such as high implementation costs and data integration difficulties may...

Continue Reading
Exploring the Launch of Lit Protocol's Innovative AI Stack

Updated Category News Views 177

Revolutionizing AI with Lit Protocol's Decentralized Agent Stack Lit Protocol is inviting developers to harness the power of a decentralized AI agent stack that facilitates on-chain agents capable of autonomous transactions. This toolkit provides developers the ability to create these innovative agents, complete with wallet keys, enabling them to transact independently...

Continue Reading
Exploring the Promise of SKB264 in Cancer Treatments

Updated Category News Views 140

Introducing SKB264: A Major Breakthrough in Cancer Treatment SKB264, also referred to as MK-2870, signifies a significant leap in cancer therapy. This advanced antibody-drug conjugate (ADC) specifically targets TROP2 and is being developed through a collaboration between Kelun Biotech and MSD. Utilizing the state-of-the-art OptiDC platform, this therapy incorporates a...

Continue Reading